TABLE 4

Summary of ARV drug concentrations at all sampled anatomic sites in TDF-FTC pod-IVR (n = 3) and TDF-FTC-MVC pod-IVR (n = 3) groups

Analyte and matrixan% above LLOQbMedian (SD)
ProximalcDistalc
TDF-FTC pod-IVR group
    Vaginal fluid (μg ml−1)
        TDF308738 (3.6 × 103)37 (3.6 × 103)
        TFV30100180 (400)110 (260)
        FTC3010012 × 103 (65 × 103)15 × 103 (72 × 103)
    CVL fluid (μg ml−1)
        TDF15930.32 (1.3)NAd
        TFV151000.23 (0.37)NA
        FTC1510025 (54)NA
    Vaginal tissue (μg g−1)
        TDF120BLLOQBLLOQ
        TFV1210035 (79)28 (16)
        FTC12100650 (260)460 (240)
    CVL cell pellet (μg sample−1)
        TDF150BLLOQNA
        TFV151000.13 (0.20)NA
        FTC151002.3 (2.4)NA
TDF-FTC-MVC pod-IVR group
    Vaginal fluid (μg ml−1)
        TDF308712 (25)13 (45)
        TFV3010061 (64)45 (54)
        FTC301001.9 × 103 (2.8 × 103)6.6 × 103 (21 × 103)
        MVC30100610 (1.7 × 103)360 (1.8 × 103)
    CVL fluid (μg ml−1)
        TDF15930.25 (1.1)NA
        TFV151000.16 (0.19)NA
        FTC151005.2 (8.4)NA
        MVC151001.3 (3.1)NA
    Vaginal tissue (μg ml−1)
        TDF120BLLOQBLLOQ
        TFV1210011 (9.6)9.2 (7.1)
        FTC12100160 (260)130 (67)
        MVC1210019 (28)23 (11)
    CVL cell pellet (μg sample−1)
        TDF150BLLOQNA
        TFV151000.065 (0.11)NA
        FTC151000.39 (0.61)NA
        MVC15930.28 (0.62)NA
  • a All values correspond to time points with the IVR in place. CVL fluid and CVL cell pellet measurements are integrated over the cervicovaginal tract.

  • b Proportion of samples that contained quantifiable drug levels.

  • c Relative to the IVR.

  • d NA, not applicable; BLLOQ, below the LLOQ.